Blood test showdown: which method spots melanoma cells better?
NCT ID NCT01558349
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared two blood test methods, EPISPOT and CellSearch, to see how well they detect circulating melanoma cells in people with advanced melanoma. Researchers took blood samples from 73 participants, including patients with stage 4 melanoma and hospitalized controls without cancer. The goal was to find out which technique is more accurate at spotting these cells, which could help improve monitoring of the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Montpellier - Hôpital Saint-Eloi
Montpellier, 34295, France
-
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma